Updates are available Correction dated 2024-09-06
Click to view Correction: https://doi.org/10.1007/s00415-024-12630-8
-
Authors
DeLuca, John https://orcid.org/0000-0003-3745-4156
- License Information
-
More Information
Article History
Received: 18 April 2024
Revised: 12 June 2024
Accepted: 15 June 2024
First Online: 5 July 2024
Change Date: 6 September 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-024-12630-8
Declarations
:
: Dr. John DeLuca received consulting fees/honorarium from Biogen, Sanofi – Genzyme, Novartis, Janssen and Bristol Myers Squibb. He has received grant funding from Biogen, Roche, Bristol Myers Squibb, EMD Serono, National Multiple Sclerosis Society (NMSS), Consortium of Multiple Sclerosis Centers (CMSC), and the National Institute of Health (NIH).
: Not applicable.
: Not applicable.
: Not applicable.
